Novo Nordisk Invests in $90M+ AI Supercomputer for Future Drug Discovery Boost
• Novo Nordisk and Nvidia are partnering to build a new AI-powered supercomputer for drug discovery that will cost $90M+.
• This supercomputer could help Novo Nordisk accelerate and improve its drug pipeline using AI and potentially quantum computing.
• However, the impact likely won't be seen for 5+ years until the facility is running and yields new drug candidates.
• Novo Nordisk's obesity drug Wegovy is driving huge revenue growth currently, lessening the need for an AI boost.
• Novo Nordisk stock remains a strong buy based on Wegovy's growth, not this long-term AI initiative.